According to CNBC, Needham initiated coverage of GE Healthcare Technologies with a buy rating and a $93 price target, implying 43% upside from Monday's close. Analyst David Saxon said the stock appears to be pricing in a bear case, creating an attractive risk-reward, and he expects AIS growth to accelerate in 2027, which could lift Street estimates. Needham said GE Healthcare is set for a turnaround after a period of underperformance and forecast mid-single-digit revenue growth and high-single-digit earnings per share growth over the next year. The firm also sees the stock reaching a price-to-earnings multiple of 17 times its 2027 estimates, versus a current forward multiple of 12.6, according to FactSet. Shares of GE Healthcare have fallen nearly 19% year to date and are down about 21% in 2026 after the company missed earnings expectations and issued weak financial outlooks because of supply constraints and other issues. Of the 21 analysts covering GE Healthcare Technologies, 14 rate it buy or strong buy and seven rate it hold, LSEG data shows.